Cancer cells are able to evolve to depend on two metabolic processes, glycolysis and oxidative phosphorylation. We spoke to Phil Jones from The University of Texas MD Anderson Cancer Center, to learn about the discovery and development of IACS-10759, identified as as a viable oxidative phosphorylation inhibitor.Read More
In the first of a two-part blog series, we discuss the advantages of a modular approach to bioinformatics with Dr. Misha Kapushesky, CEO and Founder of Genestack. Perviously a Team Leader at the European Bioinformatics Institute, we also learn about Misha's move from Institute to industry.Read More
We recently spoke to GenScript’s VP of Marketing, Eric Wang, to learn more about the company’s mission to “make people and nature healthier through biotechnology”. Eric discusses the key phases of antibody therapeutic discovery and development, GenScript’s role in advancing drug discovery research, and tells us about the company’s recently launched custom rabbit monoclonal antibody service.Read More
To learn more about ContextVision, their move into the field of digital pathology, and how INIFY™ could help benefit pathologists and patients, we spoke to Lena Kajland Wilén, Director Business Unit Digital Pathology.Read More
STING (stimulator of interferon genes) is a key mediator of innate immunity and the STING pathway has been shown to be involved in the induction of an anti-tumor immune response. We recently spoke to Andrea van Elsas, PhD, Chief Scientific Officer at Aduro Biotech to learn more about the company’s expertise in STING Pathway Activator technology.Read More
The Defense Advanced Research Projects Agency’s (DARPA) Synergistic Discovery and Design Program (SD2) hopes to update protocols with enhanced automation and machine learning strategies. As part of SD2, Ginkgo Bioworks, and Transcriptic have been offered a dual contract to help advance biological experimentation and iterative testing for synthetic biology. In this blog, we discuss the goals of SD2 and the impact of automation on research with Ben Miles, PhD, Head of Product at Transcriptic.Read More
We recently spoke to Stanislas Veillet, Chairman and CEO of Biophytis to learn more about the company’s efforts to develop first-in-class drugs to treat degenerative illnesses associated with aging.Read More
During this year’s AACR Annual Meeting we spoke to Julianna Supplee, Research Technician at the Robert and Renée Belfer Center for Applied Cancer Science at Dana-Farber Cancer Institute, to learn more about the team’s most recent study on the use of plasma HPV cell-free DNA as an early predictor of treatment response in patients with advanced oropharyngeal cancer.Read More
During this year’s AACR conference we spoke to Kang Zhang, M.D., Ph.D. from the University of California, San Diego about the collaborative work he has been doing with the Laboratory for Advanced Medicine. He discusses their recent study findings on the use of a blood-based method to look at cell-free DNA as a marker for liver cancer diagnosis and prognosis.Read More
Digital transformation, often described as the next industrial revolution, has already begun to permanently change almost every aspect of our lives.
Science, of course, is no exception. Digital transformation is poised to fundamentally change how scientists conduct research and how laboratories operate. But, what is the current state of digitalization within today’s labs, and how can they ensure they are ready for digital transformation?